阿比特龙治疗前3个月内嗜铬粒蛋白A与神经元特异性烯醇化酶变化可预测转移性去势抵抗性前列腺癌患者结局
在40例接受阿比特龙醋酸酯(AA)治疗的转移性去势抵抗性前列腺癌(mCRPC)患者中,于基线和治疗3个月后检测血清嗜铬粒蛋白A(CgA)与神经元特异性烯醇化酶(NSE)。多因素分析显示,CgA与NSE联合阳性及治疗前3个月内任一标志物升高均为总生存(OS)、影像学无进展生存(rPFS)和前列腺特异性抗原无进展生存(PSA-PFS)的独立预测因素。
要点
- 基线CgA与NSE联合阳性是mCRPC患者接受AA治疗后的独立预后因素。
- AA治疗前3个月内CgA或NSE升高可预测OS、rPFS和PSA-PFS较差。
- 系列检测CgA和NSE可能帮助识别从AA治疗中获得最佳生存获益的患者。
核心结论
- AA治疗前3个月内CgA和NSE升高以及基线CgA和NSE水平升高是接受AA治疗的mCRPC患者OS、rPFS和PSA-PFS的独立预后因素。
- 系列CgA和NSE评估可能帮助临床医生区分从AA治疗中获得最佳生存获益的mCRPC患者。
研究设计与样本
- 在40例mCRPC患者中,于基线及AA治疗3个月后检测血清CgA和NSE水平。
- 结局指标为PSA-PFS、rPFS和OS。
主要发现
- CgA水平与NSE水平不相关(P=0.296)。
- 多因素分析中,CgA与NSE联合(≥1个标志物阳性 vs 两个标志物均阴性)是OS、rPFS和PSA-PFS的显著预测因素。
- 多因素分析中,AA治疗前3个月内CgA与NSE联合升高(≥1个标志物阳性 vs 两个标志物均阴性)是OS、rPFS和PSA-PFS的显著预测因素。
临床怎么用
- 原文结论提示系列CgA和NSE评估可能帮助临床医生区分从AA治疗中获得最佳生存获益的mCRPC患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the prognostic utility of serum chromogranin A (CgA) and neurone-specific enolase (NSE) variations during the first 3 months of abiraterone acetate (AA) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: The serum levels of CgA, NSE were measured at baseline and after 3 months of AA treatment in 40 patients with mCRPC. Outcome measures were prostate-specific antigen progression-free survival (PSA-PFS), radiographic PFS (rPFS), and overall survival (OS). RESULTS: CgA levels were not correlated with NSE levels (P = 0.296). In multivariate analysis the combination of CgA and NSE (≥1 marker positive vs both markers negative) and the combination of CgA and NSE elevation during the first 3 months of AA treatment (≥1 marker positive vs both markers negative) remained significant predictors of OS, rPFS, and PSA-PFS. CONCLUSION: We found that CgA and NSE elevation during the first 3 months of AA treatment and elevated baseline CgA and NSE levels were independent prognostic factors for OS, rPFS and PSA-PFS in patients with mCRPC treated with AA. This suggests that serial CgA and NSE evaluation may help clinicians in distinguishing patients with mCRPC who would obtain the best survival benefit from AA treatment.
引用
- Fan L, Wang Y, Chi C, et al. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. BJU Int. 2017. PMID: 28107595. doi:10.1111/bju.13781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。